Malcolm Weir has been promoted to the role of executive vice chairman of Sosei Group Corp with responsibility for strategic oversight of all platform technology, R&D and early drug development at Sosei Heptares, the Japanese company’s operating business. Dr Weir is the co-founder of Heptares Therapeutics, which specialises in structure-based drug design. Heptares and was acquired by Sosei in 2015. He was most recently Sosei Group’s executive vice president for research and early development.
Separately, Rolf Soderstrom has been appointed external director of Sosei. He was previously chief financial officer at BTG Plc, which was acquired by Boston Scientific Corp in 2019.
Sosei Heptares announced the appointments on 25 March 2020.
Copyright 2020 Evernow Publishing Ltd